Association of E-cadherin & vimentin expression with clinicopathological parameters in lingual squamous cell carcinomas & their role in incomplete epithelial mesenchymal transition

Neelakshi Goyal¹, Meeta Singh¹, Nishant Sagar¹, Nita Khurana¹ & Ishwar Singh²

Departments of ¹Pathology & ²Otolaryngology, Maulana Azad Medical College, New Delhi, India

**Background & objectives:** Lingual squamous cell carcinomas (SCC) pose a major public health burden in India. Epithelial-mesenchymal transition (EMT) is the conversion of an epithelial cell to a mesenchymal phenotype at the invasive front (IF) enhancing invasiveness of these cells which may be studied using immunohistochemistry. The objective of this study was to assess the expression of E-cadherin and vimentin at the IF, and their correlation with the histological risk assessment score, clinicopathological parameters and lymph node metastasis.

**Methods:** Thirty consecutive untreated patients diagnosed as lingual SCC who underwent hemiglossectomy over one year formed the study group. The immunohistochemical expression of E-cadherin and vimentin in the periphery as well as the centre of tumour islands was correlated with clinicopathological parameters, Brandwein-Gensler risk assessment score and lymph node metastasis, along with a correlation between the coexpression of two markers at the IF.

**Results:** Loss of E-cadherin expression was seen at IF in 83.3 per cent (25/30) cases. Out of these, 20 per cent (5/25) showed a corresponding gain in vimentin expression (complete epithelial-mesenchymal transition) and 80 per cent (20/25) did not. Overall, 16.6 per cent (5/30) cases showed complete EMT. However, no correlation between E-cadherin and vimentin expression at the IF was found. No statistical significance was found between E-cadherin loss and vimentin gain at the IF, with the various parameters or the risk score.

**Interpretation & conclusions:** The present study suggests that the cells at IF may metastasize even without a gain in vimentin expression (without classical EMT), as cohesive clusters showing incomplete EMT (E-cadh-/Vim-).

**Key words** E-cadherin - epithelial to mesenchymal transition - lingual squamous cell carcinomas - risk score - vimentin

Oral cancer is the sixth-most common cancer in the world⁴. India has age-standardized incidence rates of 12.9 per 100,000 for men². Tongue is the most common site in the western world with increasing incidence in India and squamous cell carcinoma (SCC) as the most common histological type⁴. Tumour cells progress from the pre-invasive stage and infiltrate the surrounding tissues and muscles before metastasizing to cervical lymph nodes, by loss of intercellular adhesion molecules and transition into mesenchymal phenotype⁴. Cells at the leading edge of a tumour have the maximum potential to infiltrate, hence the invasive
front (IF) is the most important area to be assessed for epithelial to mesenchymal transition (EMT)\textsuperscript{4}.

E-cadherin mediates intercellular adhesion and is expressed normally in the stratum spinosum of the oral mucosa\textsuperscript{5}. As it maintains the cohesiveness of the cells, its loss or downregulation is associated with the process of EMT\textsuperscript{6}.

Vimentin is a mesenchymal marker and a type III intermediate filament protein\textsuperscript{7}. Vimentin is expressed on the endothelial cells, lymphocytes and fibroblasts but not by normal epithelial cells\textsuperscript{8}. It has been associated with invasiveness and an increased metastatic potential of tumour cells\textsuperscript{9}. It is known to be a marker of EMT\textsuperscript{4}.

Besides the histological grade, depth of invasion (DOI) and the lymph node status, a histopathological risk assessment score may depict the prognosis of these tumours. Brandwein-Gensler et al\textsuperscript{10} gave a score based on the cellular pattern of invasion (POI) as proposed by Bryne et al\textsuperscript{11}, lymphocytic infiltrate (LI) at the tumour-host interface and perineural invasion (PNI) by malignant cells. Based on these criteria, they stratified the cases into low-risk (score 0), intermediate risk (score 1/2) and a high-risk group (Score 3-9)\textsuperscript{10}.

Although a few studies have correlated the occurrence of EMT with histomorphological parameters and lymph node metastases using immunoexpression of E-cadherin and vimentin, its correlation with such a composite risk score model is lacking\textsuperscript{12-14}.

The expression of E-cadherin and vimentin in lingual SCC at the central superficial area (CSA) and IF of the tumour islands, and its correlation with the clinicopathological parameters, the Brandwein-Gensler risk assessment score and lymph node metastasis was studied. A correlation between the co-expression of the two markers at the IF was also studied.

**Material & Methods**

The study was conducted in the departments of Pathology and Otorhinolaryngology, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi over one year (April 2017-2018). Institutional Ethical clearance was sought before carrying out the study.

**Inclusion criteria:** Thirty hemiglossectomy specimens, from consenting patients above the age of 18 yr, diagnosed with lingual SCC on histopathology were included in the study. These patients were consecutively recruited.

**Exclusion criteria:** Specimens from patients with a history of preoperative radiotherapy or chemotherapy were excluded.

**Sample size:** The sample size was calculated using the formula
\[
N = \frac{4pq}{d^2}
\]

[where, \(p\) = prevalence, \(q\) = 100 - \(p\), \(d\) = precision of the estimate (10% or 20% of \(p\))]\

For E-cadherin,

\[
N = \frac{4 \times 75 \times 25}{(10/100 \times 75)^2} = 133
\]

(10% precision)

For Vimentin,

\[
N = \frac{4 \times 30 \times 70}{(10/100 \times 30)^2} = 933
\]

(10% precision)

**Parameters assessed:** Clinicopathological parameters such as age, gender, duration of symptomatology (<7 or \(\geq 7\) months)\textsuperscript{15}, history of smoking and alcohol intake, presence of a growth or ulcer and tumour size (in greatest dimension on gross examination) were assessed. Routinely processed, formalin-fixed paraffin-embedded, haematoxylin and eosin-stained sections were evaluated microscopically.

The DOI was measured from the basement membrane, of the adjacent normal mucosa and then by drawing a hypothetical ‘plumb line’ from this plane to the deepest point of tumour invasion\textsuperscript{16}. Histological typing and grading were done as per the WHO classification, into well, moderate and poorly differentiated SCC\textsuperscript{1}. Pathological staging was done as per tumour, nodes, metastases (TNM) classification\textsuperscript{17}.

POI was characterized as per Bryne et al\textsuperscript{11}; (i) type 1-tumour invasion in a broad pushing pattern; (ii) type 2-broad pushing tumour islands with the stellate pattern; (iii) type 3-islands of >15 tumour cells; (iv) type 4-islands of <15 cells or cord-like or single-cell invasions (Fig. 1A-C); (v) type 5-tumour satellites of any size with 1 mm of intervening normal tissue (fibrosis not to be taken) at the tumour/host interface. POI type 1, 2 and 3 was assigned point 0, type 4 was given 1 point and type 5 was given 2 points\textsuperscript{10}.
If the tumour displayed more than one POI, the worst POI was considered.

LI was graded as: (i) type 1-continuous and dense rim of lymphocytes at the interface (point 0, Fig. 1C); (ii) type 2-discontinuous patches of dense lymphoid tissue (point 1) and (iii) type 3-limited response or no lymphoid response (point 3)\(^\text{10}\). PNI was assessed as absent (point 0), in smaller nerves with diameter <1 mm (point 1) and in larger nerves with diameter >1 mm (point 3)\(^\text{10}\) (Fig. 1D).

An overall risk score was given and classified as score 0, score 1 or 2 and score 3-9\(^\text{10}\).

**Immunohistochemistry:** Immunohistochemistry was done on sections from the tumour by the biotin-avidin technique using primary antibodies for E-cadherin (mouse monoclonal antibody, Biogenex, RTU, Fremont, CA, USA) and vimentin (mouse monoclonal antibody, Biogenex, RTU, Fremont, CA, USA). The sections were deparaffinized and blocked for endogenous peroxidase in 3 per cent \(\text{H}_2\text{O}_2\) in methanol. Overnight incubation with primary antibody overnight (at 4\(^\circ\) C) and, secondary and tertiary antibodies (peroxidase labelled streptavidin-peroxidase complex) for 30 minutes each was done with three washes in PBS buffer after each incubation. DAB (ES005, Temecula, California) was applied after the last wash and the reaction monitored under microscope. Counterstain with haematoxylin was done after crisp brown cytoplasm and membrane staining was seen. The adjacent mucosal epithelium was taken as a positive control for E-cadherin (Fig. 2A). Stromal cells, muscle bundles and nerve fibres was taken as positive control for vimentin (Figs 2B and D). Negative controls were obtained by omitting the primary antibodies.

Immunohistochemistry was evaluated at the CSA and IF of the tumour. Expression of both E-cadherin as well as vimentin was classified as described previously\(^\text{4}\).

(i) **E-cadherin expression:**

(a) Preserved: >50 per cent epithelial tumour cells showing membranous immunostaining (brown granular membranous reaction in the tumour cells) Fig. 2C or

(b) Reduced: 50 per cent or less epithelial tumour cells showing membranous immunostaining. Non-specific staining of acantholytic tumour cells and keratin material was ignored.

(ii) **Vimentin expression:**

(a) Negative: <10 per cent epithelial tumour cells showing cytoplasmic immunostaining or

(b) Positive: 10 per cent or more epithelial tumour cells showing cytoplasmic immunostaining (membranous or cytoplasmic brown granular reaction in tumour cells away from the tumour/
A B

Fig. 3. (A) Brown granular membranous E-cadherin positivity in centre of tumour islands (×200). (B) Vimentin positivity in cytoplasm of tumour cells at the infiltrating edge of the tumour (×200).

stromal interface). Non-specific staining of cells abutting the stroma was ignored.

Statistical analysis: Association between E-cadherin and vimentin expression, the clinicopathological parameters, the risk assessment score and the lymph node status was expressed in simple percentages. McNemar’s test was applied to assess the difference in expression of both E-cadherin and vimentin, at the IF and the central area of the tumour islands, separately. While the Spearman’s co-efficient correlation was used to assess the correlation at the centre of the tumour. All data were analyzed using Statistical Package for the Social Science Software Version 16 (IBM, New Delhi).

Results & Discussion

The patients were age from 26 to 71 yr with mean of 45.73 yr. Out of 30 cases, females were 33.3 per cent (10/30) and males 66.7 per cent (20/30). Majority of the patients, 76.67 per cent (23/30) had clinical symptoms within ≤7 months. History of chewing/smoking tobacco, 93.33 per cent (28/30), 53.3 per cent (16/30) alcohol consumption, and both alcohol and tobacco with 43.3 per cent (13/30).

Presentation with an ulceroproliferative growth (56.66%, 17/30) and non-healing ulcer (43.33%, 13/30) was documented. The tumour size ranged from 0.8 to 5.2 cm with a mean of 2.33 cm and standard deviation (SD) of 1.18.

Mean DOI was found to be 6.83 mm ± 5.16. Tumour differentiation was categorically, well (33.3%, 10/30), moderate (63.3%, 19/30) and poor (3.3%, 1/30) respectively. Lymph node involvement was 36.7 per cent (11/30). TNM staging showed stage I-13 tumours, stage II-5 tumours, stage III-6 tumours and stage IV - 6 tumours. Patients presenting earlier (duration <7 months) had stage I/II disease (a lower stage) (13/18, 72.2%), whereas patients presenting later (≥ 7 months) had stage III/IV disease (7/12, 58.3%) (a higher stage), however the P value for this finding was insignificant (P=0.136).

Risk assessment score: The cases were assigned points for PNI (point 0 - 14/30, 1- 8/30, 3- 8/30), L1 (point 0 - 17/30, 1-11/30, 3 - 2/30) and for POI (point 0 - 16/30, 1-14/30, 2 - 0) and scored according to their risk assessment. Overall, 50 per cent cases (15/30) were intermediate score (point 0), 33.3 per cent were high risk (points 1-2) and 16.7 per cent low risk (Points 3-9). All five cases with a low-risk score showed a type 1, 2 or 3 POI and absence of PNI. No correlation was found between the risk groups and tumour size, DOI, PNI or the lymph node metastases. On grouping intermediate and high-risk categories together, 56 per cent (14 out of 25) of those with an intermediate/high score showed a type 4 POI (P=0.045) and 64 per cent (16 out of 25) showed the presence of PNI (P=0.014) (Table I).

Evaluation of immunohistochemistry (IHC) at central superficial area (CSA) and invasive front (IF): Loss of E-cadherin expression at both IF and CSA was observed in 3 tumours (10%), preserved expression at CSA and IF was seen in five tumours (16.67%) and a majority, 22 tumours (73.33%) only showed a loss at IF (Fig. 3A). None showed a loss of E-cadherin expression at CSA with preserved expression at IF. Expression of E-cadherin showed a significant decrease at the interface when compared to the expression at CSA (P<0.05).

Lack of vimentin expression at both IF and CSA was observed in 17 tumours (56.67%), gain in expression at IF only was seen in eight tumour (26.67%) (Fig. 3B) and positive expression at CSA was only seen in five tumour (16.66%). No significant result was found in the expression of vimentin at IF when compared with the CSA of tumour island (P>0.05). Also, no correlation of E-cadherin and vimentin (Table II) with clinic pathological parameters was found.

Correlation of immunohistochemistry (IHC) at the invasive front (IF): Loss of E-cadherin at IF of the tumour islands was seen in 25 cases whereas its positivity was maintained at CSA of the tumour islands in 27 cases. In three cases, loss of E-cadherin was seen at both the CSA and IF. However, a corresponding gain in vimentin expression was seen only in 8 cases.
Of these, only five showed a corresponding loss of E-cadherin \((P>0.05)\). A correlation between the loss of E-cadherin at IF with a corresponding gain in vimentin was not found.

Grouping intermediate and high-risk groups together, a correlation was found with the presence of
PNI and a worse POI (pattern 4). No correlation was found with lymph node metastases or stage of tumour.

Due to permanent differentiation, cells in the body perform specific functions, but activation of EMT can modify cell phenotype by transdifferentiation and convert to mesenchymal cells. Loss of normal interaction of the epithelial cell with the basement membrane enhances migratory capacity, invasiveness and resistance to apoptosis. This leads to an increased chance of metastasis and secondary tumours.

E-cadherin and vimentin can demonstrate EMT at IF, as by loss of E-cadherin, the cells lose epithelial phenotype, show increased invasiveness and a tendency to metastasize by acquiring fibroblastic morphology. Vimentin is increased in poorly differentiated variants of SCC and sarcomatoid differentiation.

A significant decrease in E-cadherin at IF compared to CSA has been reported earlier with a significant gain in vimentin at IF, as in the present study, however, there are contrary reports.

The correlation of E-cadherin expression at the IF with clinicopathological parameters, risk score and lymph node metastases showed no statistical significance similar to other studies, including parameters such as age, gender, size or stage of the tumour, worsening pattern of tumour differentiation. Based on similar results, it shows that expression of immunomarkers such as E-cadherin may not have an impact on the biological behaviour of these tumours.

The expression of vimentin at IF showed no correlation in the present study, as was seen in a few other studies that showed similar lack of significant correlation with lymph node metastases, age, gender, histological differentiation, POI, size and stage of tumour. Contrasting with a positive correlation of Vimentin positivity at IF with lymph node metastasis degree of differentiation, clinical stage and POI.

At the IF, 80 per cent cases (20/25) which showed a loss of E-cadherin did not have a corresponding gain in vimentin. Only a few cases (5 out of 30) showed an actual EMT phenotype (E-cadh+/Vim-). Another 6.67 per cent cases (2/30) showed preserved E-cadherin expression with no gain in vimentin positivity (E-cadh+/Vim-) and 20 out of the 30 cases were negative for both. (E-cadh-/Vim-). This suggests that mechanisms other than EMT may be involved in the invasiveness of the tumours and loss of an epithelial phenotype may not always be associated with a gain of mesenchymal phenotype, and the two events may occur independent of each other. Tumour cells are in a particular phase of their life cycle at IF, and the phenotypes encountered could be the most common pattern during that transit, hence EMT may not be the only mode of invasion, rather an entire range of intermediate invasion phenotypes showing loss or gain of proteins may occur. Complete EMT and collective cell invasion (CCI) form the ends of this spectrum.

Thirteen tumours showed vimentin positivity in the present irrespective of location (whether at IF or CSA), suggesting perhaps EMT is not exclusively a phenomenon at IF.

CCI is another mode of invasion where cells migrate as collective groups that detach from the primary tumour, still adherent to each other and metastasize. These invade the adjacent matrix and tissues as aggregates, clusters, retaining their intercellular adhesion molecules without expressing mesenchymal protein. They lose their cell adhesion molecules but do not gain mesenchymal markers, which explains the variable expression of these proteins at IF in the present study (20 cases, E-cadh-/Vim-).

Similarly, only small number of cases in few studies showed complete EMT, giving credence to CCI as a mode of invasion and that gain in vimentin is not necessary for tumour cells to metastasize.

Overall in the present study, a correlation between worse POI and the presence of PNI was found in the intermediate/high-risk category group vs the low-risk group. Also, a significant loss of expression of E-cadherin at IF with only a few cases demonstrating a
corresponding gain in vimentin, was seen, suggesting that incomplete EMT/CCI may operate at IF in lingual SCC, affected by the type of stroma of parent tissue. So, the sample size in the present study was small with a limited immunohistochemistry panel. Also, the immunoexpression was not confirmed using PCR due to resource limitation. Despite these shortcomings, the present study suggests that immunoexpression at IF may not necessarily correlate with the varying degrees of tumour aggressiveness.

**Financial support & sponsorship:** None.

**Conflicts of Interest:** None.

**References**

1. Sloan P, Gale N, Hunter K, Lingen M, Nylander K, Reibel J, et al. Malignant surface epithelial tumours. In: El-Naggar AK, Chan JK, Grandis JR, Takata T, Slaugtvej PJ, editors. WHO classification of head and neck tumours. Lyon: IARC Press; 2017. p. 108-11.

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 : 394-424.

3. Indian Council of Medical Research. Consensus document for management of tongue cancer. New Delhi: ICMR; 2014.

4. Cheng SY, Shi K, Bai XR, Wu QW, Lv QX. Double-staining of E-cadherin and podoplanin offer help in the pathological diagnosis of indecisive early-invasive oral squamous cell carcinoma. Int J Clin Exp Pathol 2018; 11 : 38-47.

5. Kariche N, Moulai N, Sellam LS, Benyahia S, Ouahione W, Djenannou D, et al. Expression analysis of the mediators of epithelial to mesenchymal transition and early risk assessment of therapeutic failure in laryngeal carcinoma. J Oncol 2019; 2019 : 5649846.

6. Afrem MC, Mărgăritescu C, Crăițoiu MM, Ciucă M, Şarăţ CG, Cotoi OS. The immunohistochemical investigations of cadherin “switch” during epithelial-mesenchymal transition of tongue squamous cell carcinoma. Rom J Morphol Embryol 2014; 55 : 1049-56.

7. Park S, Ahn HK, Lee DH, Jung Y, Jeong JW, Nam S, et al. Systematic mutation analysis in rare colorectal cancer presenting ovarian metastases. Sci Rep 2019; 9 : 16990.

8. Zhou J, Tao D, Xu Q, Gao Z, Tang D. Expression of E-cadherin and vimentin in oral squamous cell carcinoma. Int J Clin Exp Pathol 2015; 8 : 3150-4.

9. Jain AP, Patel K, Pinto S, Radhakrishnan A, Nanjappa V, Kumar M, et al. MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. Sci Rep 2019; 9 : 18793.

10. Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, Hille JJ, et al. Oral squamous cell carcinoma: Histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 2005; 29 : 167-78.

11. Bryne M, Koppang HS, Lillegård R, Kjaerheim A. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 1992; 166 : 375-81.

12. Semelakova M, Grauzam S, Betadthunga P, Tiedeken J, Coaxun S, Neskey DM, et al. Vimentin and non-muscle myosin IIA are members of the neural precursor cell expressed developmentally down-regulated 9 (NEDD9) interactome in head and neck squamous cell carcinoma cells. Transl Oncol 2019; 12 : 49-61.

13. Angadi PV, Patil PV, Angadi V, Mane D, Shekar S, Hallikerimath S, et al. Immunexpression of epithelial mesenchymal transition proteins E-cadherin, β-catenin, and N-cadherin in oral squamous cell carcinoma. Int J Surg Pathol 2016; 24 : 696-703.

14. Suresh TN, Hemalatha A, Harendra Kumar ML, Azeem Mohiyuddin SM. Evaluation of histomorphological and immunohistochemical parameters as biomarkers of cervical lymph node metastasis in squamous cell carcinoma of oral cavity: A retrospective study. J Oral Maxillofac Pathol 2015; 19 : 18-24.

15. Najeeb T. Clinicopathological presentation of tongue cancers and early cancer treatment. J Coll Physicians Surg Pak 2006; 16 : 179-82.

16. Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67 : 122-37.

17. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 7th ed. Chicago, Illinois: Springer; 2010. p. 1-3.

18. Danese E, Montagnana M, Lippi G. Circulating molecular biomarkers for screening or early diagnosis of colorectal cancer: Which is ready for prime time? Ann Transl Med 2019; 7 : 610.

19. Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: Association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumour features. Cancer 2008; 112 : 2088-100.

20. Cruz MC, Pereira AL, Lopes FF, Nonaka CF, Silva RR, FreitasRe A, et al. Immunohistochemical expression of E-cadherin and CD44v6 in squamous cell carcinomas of the lower lip and tongue. Braz Dent J 2009; 20 : 64-9.

21. Nijkamp MM, Span PN, Hoogstooten IJ, van der Kogel AJ, Kaanders JH, Bussink J. Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol 2011; 99 : 344-8.

22. Etemad-Moghadam S, Alaeddini M. Pattern of invasion in squamous cell carcinomas of the lower lip and oral cavity. J Oral Biol Craniofac Res 2017; 7 : 167-70.
23. Hesse K, Satzger I, Schacht V, Köther B, Hillen U, Klode J, et al. Characterisation of prognosis and invasion of cutaneous squamous cell carcinoma by podoplanin and E-cadherin expression. *Dermatology* 2016; 232: 558-65.

24. Nakashima Y, Yoshinaga K, Kitao H, Ando K, Kimura Y, Saeki H, et al. Podoplanin is expressed at the invasive front of esophageal squamous cell carcinomas and is involved in collective cell invasion. *Cancer Sci* 2013; 104: 1718-25.

25. Wu RF, Chen ZX, Zhou WD, Li YZ, Huang ZX, Lin DC, et al. High expression of ZEB1 in endometriosis and its role in 17β-estradiol-induced epithelial-mesenchymal transition. *Int J Clin Exp Pathol* 2018; 11: 4744-58.

For correspondence: Dr Meeta Singh, Department of Pathology, Maulana Azad Medical College, New Delhi 110 002, India

E-mail: meetamamc@gmail.com